ArticleMedicine2026
Real-world off-label apixaban dosing and clinical outcomes in patients with heart failure and end-stage kidney disease.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apixaban plays a crucial role in preventing cardioembolic events in patients with nonvalvular atrial fibrillation (NVAF). However, in clinical practice, physicians often adjust apixaban dosing based on kidney function, deviating from guideline-recommended dosing. This study investigated the effects of real-world, off-label apixaban dosing on long-term outcomes in patients with heart failure (HF), NVAF, and end-stage kidney disease (ESKD). We analyzed data from a HF registry of patients with NVAF and ESKD between 2018 and 2024. The inclusion criteria comprised all patients treated with apixaban. Patients were categorized according to the strength of the apixaban dose administered. Outcomes, including bleeding events, systemic thromboembolic events, and all-cause mortality, were compared. Among 480 patients, 265 (55.2%), with a mean age of 77.3 ± 10.1 years, received an off-label underdose of apixaban. Baseline characteristics, including CHA2DS2-VASc and HAS-BLED scores, were similar across groups. Over a median follow-up of 48 months, no significant differences in systemic thromboembolic events or mortality were observed between the off-label underdose group and those receiving standard doses or off-label overdoses (P = .705). Similarly, no significant differences were observed in bleeding risk (underdose vs standard, P = .600; overdose vs standard, P = .395; underdose vs overdose, P = .469). In multivariate analysis, the CHA2DS2-VASc score was an independent predictor of thromboembolic events (odds ratio 1.818, 95% confidence interval 1.081-3.058; P = .024). In patients with HF, NVAF, and ESKD, off-label apixaban dosing was not associated with an increased risk of systemic thromboembolic events, mortality, or bleeding, highlighting the potential for personalized apixaban dosing based on patient-specific factors and pharmacokinetics, particularly in Asian populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.